Endometrial cancer (EC) is the most common gynecologic malignancy prevailing after menopause.
Introduction
Endometrial cancer (EC) is the most common gynecologic cancer and the fourth most frequent neoplasm in women in North America, predominantly occurring in postmenopausal women. Furthermore, EC is the only gynecologic cancer with a rising incidence and mortality [1] . Curative surgery, alone or combined with adjuvant radiation therapy, is performed when cancer is limited to the uterus. However, a subset of EC patients experience recurrence, shorter survival and display inadequate response rates to cytotoxic chemotherapy [2] . The prognosis of EC is determined primarily by disease stage, grade and histologic subtype, reinforcing the need to explore novel prognostic markers.
EC is a heterogeneous disease comprising two types based on histology. The most common type, which accounts for nearly 80% of cases, is the endometrioid or Type I adenocarcinoma, associated with unopposed estrogen stimulation and generally has good prognosis. Type II is nonendometrioid that includes serous, clear cell, mixed carcinoma, with higher-grade histology and carries an adverse prognosis. Studies originally described Type I EC as estrogen-dependent whereas Type II was not.
However, recent studies indicate that steroid hormones may play a significant etiological role in both types [3] . EC prevails after menopause when ovaries have ceased to secrete potent estrogens. Obesity is a known risk factor of EC [4] and this may be partly related to the fact that adipose tissue represents a major source of estrogen synthesis in postmenopausal women, actively converting adrenal and androgen precursors to estrogens resulting in increased serum bioavailable estradiol (E 2 ) [5, 6] . Previous work by our group and others has revealed that the potent estrogen E 2 primarily derive from conversion of estrone-sulfate (E 1 -S) in EC tumors rather than aromatization of androgens by the aromatase (CYP19), which has barely detectable expression levels in EC cells [7] [8] [9] [10] . Besides, E 2 and E 1 may be converted into numerous biologically active derivatives with varying mitogenic and genotoxic properties by the action of various cytochrome P450 and catechol-O-methyl transferase enzymes [11] . This metabolism involves the irreversible hydroxylation (OH) at the C-2, C-4, or C-16 positions of the steroid ring and the methylation of C-2 or C-4 hydroxyl group. The latter prevents formation of mutagenic catechol quinones derived from hydroxyl estrogens that form stable and depurinating DNA adducts. In vitro and in vivo studies further support that 2-methoxyestradiol (2-MeOE 2 ) has strong anticancer activity [12, 13] . In addition, these metabolites can be converted to their inactive sulfate and glucuronide conjugates. Recent 4 studies have assessed the risk of EC in relation to steroid hormones, yet none have explored their association with prognosis [4, 14] .
In a cohort of 246 postmenopausal women undergoing hysterectomy for a newly diagnosed endometrial cancer, we analyzed the levels of 27 steroids in serums collected the morning of surgery and one month after surgery. Steroid measures included the assessment of endogenous concentrations of adrenal precursors, androgens, potent estrogens and catechol estrogens using sensitive and specific mass spectrometry (MS) validated assays. Our primary goal was to evaluate the association between circulating steroid levels, clinicopathological features and the risk of recurrence after surgery. A group of 110 healthy postmenopausal women was also included to examine the association between steroid hormones and EC status.
2.Materials and Methods

Study populations
All participants provided a written informed consent for their participation to the study and the use of their specimens. The current study was reviewed and approved by our institutional review boards. Recruitment of healthy postmenopausal women, as well as specimen collection and treatments, have been described elsewhere [15] . Briefly, women were recruited in a mammography clinic in Quebec City (QC, Canada) between July 2003 and March 2004. To be eligible, women had to: 1) be of postmenopausal status, 2) have no history of health problems related to steroid hormone metabolism, 3) have no history of hepatic, thyroid, or adrenal diseases, and 4) have not taken hormone replacement therapy (HRT) during the three months preceding enrolment. Recruitment methods and specimen collection of EC cases have been described [16] . Participants were all recruited at the Hôtel-Dieu de Québec Hospital (Québec City), between 2002 and 2013. All women were of postmenopausal status, undergoing surgery for EC (hysterectomy and bilateral salpingo-oophorectomy) and had not taken HRT in the three weeks prior to surgery. Blood samples were collected the morning of surgery and one month after surgery as part of a follow-up appointment. Samples were immediately processed, separated in aliquots and stored at -80°C until analysis. EC recurrence was ascertained by computerized tomography scan. For both cohorts, demographic and anthropometric data were collected through nurse-administered questionnaires, whereas information regarding drug use (including oral contraceptive and HRT) and obstetric history were collected at the same time. A pathologist assessed the histopathological characteristics of the hysterectomy specimen. Systematic assembling and review of medical records was performed by one of the treating gynecologic oncologist (J.G.).
acetate and acetone were purchased from VWR (Montréal, QC, Canada). Ascorbic acid, sodium bicarbonate, b-glucuronidase/sulfatase (Helix Pomentia Type HP-2) and dansyl chloride were purchased from Sigma (Oakville, ON, Canada).
Steroids and SHBG quantification
Steroids and SHBG were quantified using validated methods [16, 17] . Internal standards (deuterated steroids) were added to samples and quality controls were included in each run. The measured steroids and their limits of quantification were as follows: dehydroepiandrosterone (DHEA; 100 pg/mL); androstenediol (5-diol; 50 pg/mL); testosterone (30 pg/mL); dihydrotestosterone (DHT; 10 pg/mL); androsterone (ADT; 50 pg/mL); estrone (E 1 ; 5 pg/mL); estradiol (E 2 ; 1 pg/mL); androstenedione (4-dione; 50 pg/mL); ADT-glucuronide (ADT-G; 1 ng/mL); androstane-3a, 17b-diol 3-glucuronide (3a-diol-3G; 0.25 ng/mL); 3a-diol-17-G (0.25 ng/mL); DHEA-sulfate (DHEA-S; 0.075 mg/mL); estrone-sulfate (E 1 -S; 0.075 ng/mL). Briefly, gas-chromatography (GC) coupled to mass spectrometry (MS) were used to quantify levels of DHEA, ADT, 5-diol, 4-dione, testosterone, DHT, E 1 and E 2 using 250 µL of serum, while liquidchromatography (LC) tandem MS was used for conjugated steroids using 20 µL for sulfates and 100 µL for glucuronides in two independent assays. All metabolite coefficients of variation (CV) were <10% and no samples had undetectable hormone levels.
We also measured 14 catechol estrogens with another MS-based assays, namely i) catechol 2OH: 2-hydroxyestrone (2-OHE 1 ), 2-hydroxyestradiol (2-OHE 2 ), ii) catechol 4OH: 4-hydroxyestrone (4-OHE 1 ), 4-hydroxyestradiol (4-OHE 2 ), iii) catechol 16OH: estriol (E 3 ), 16α-hydroxyestrone (16α-OHE 1 ), 16-ketoestradiol (16-ketoE 2 ), 16-epiestriol (16-epiE 3 ), and 17-epiestriol (17-epiE 3 ), and iv) catechol MeO: 2-methoxyestrone (2-MeOE 1 ), 2-methoxyestradiol (2-MeOE 2 ), 2-hydroxyestrone-3-methyl ether (3-MeOE 1 ), 4-methoxyestrone (4-MeOE 1 ) and 4-methoxyestradiol (4-MeOE 2 ). The quantification method was performed after some adjustments (described below) by stable isotope dilution LC/MS-MS based on method published by Xu et al [18] , which detected 13 catechol estrogens in addition to E 1 and E 2 and used 500 µL for a reported lower limit of quantification (LLOQ) of 8 pg/mL. In our study, we used 250 uL of serum for extraction to measure 14 catechol estrogens with a LLOQ of 5 pg/mL (corresponding to 16.56-18.52 pmol/L depending on the estrogen metabolite). LLOQ was defined as the minimum value at which the ratio of signal-to-noise was ≥5:1. Also, values of catechol estrogens observed below LLOQ (even if detected above the limit of detection) were considered as undetected. To measure total catechol estrogens corresponding to the sum of conjugated plus unconjugated forms, b-glucuronidase/sulfatase was included in sample preparation. Briefly, catechol estrogens were extracted from 250 µL of serum with Backward stepwise (likelihood ratio) was used for the selection of covariates included in the final model, in which hormone concentrations (categorized upon tertiles or the median when specified) were added.
For assessment of risk of recurrence, a similar method was used, with the median level of EC cases as the category threshold. For survival and recurrence analyses, patients were also categorized as low or high risk of poor prognosis, based on histological types (T) and grade (G): TI-G1 or TI-G2 were considered at low risk, whereas TII and TI-G3 were considered at high risk [19] . Differences in steroid concentrations between groups were assessed using the analysis of covariance (ANCOVA) on logtransformed data, and untransformed data are presented to facilitate understanding. Fold changes were calculated upon the median of each group. For pairwise comparison of more than two groups, the TukeyKramer post hoc test was used. The hormone variation between paired blood samples (preoperative and postoperative samples were available for 187 cases) was analyzed using Wilcoxon signed rank test, whereas variation between groups was compared by ANCOVA on the difference of paired preoperative and postoperative levels (log-transformed). The overall survival (OS) (all-cause mortality) was estimated with the Kaplan-Meier method and tested using log-rank test, while Cox regressions were used for further adjustments using backward stepwise (likelihood ratio) for the selection of covariates. Cancer-specific survival could not be not analyzed. Because of the exploratory nature of the study and the significant interrelations between circulating steroids, two-sided P-values were considered statistically significant at P<0.05, without adjustment for multiplicity. Covariates adjustments are specified in figure and table legends.
Results
A cohort of 246 postmenopausal EC cases treated by hysterectomy
We studied a cohort of 246 postmenopausal EC cases prospectively recruited at a single center and all treated by hysterectomy performed for curative intent. Most cases (82%) presented with a Type I adenocarcinoma and 18% were histologically characterized by serous, clear cell, mucinous, or mixed carcinoma; combined as Type II ( Table 1 ). The mean follow-up time after recruitment was 65.5 months and 26 patients experienced recurrence after surgery for a recurrence incidence of 10.6%. (6.4% Type I and 29.5% Type II). The estimated 5-year recurrence incidence was of nearly 10% (n=24 cases). Of note, the majority of Type I cases who experienced relapse (12 out of the 13) were of low-grade and particularly of grade 2 (67%), whereas for Type II, 82% recurrent cases were of grade 3. EC relapse and OS were related to a more aggressive disease (myoinvasive tumors, presence of metastatic nodes) but not BMI ( Table 2) . Only OS was associated with age (HR=1.08, 95% CI=1.04-1.12; P<0.001 for OS).
Estradiol metabolites are associated with recurrence and survival
In serum samples collected on the morning of surgery and one month later, we initially profiled 13 unconjugated (using gas chromatography-mass spectrometry (GC-MS)) and conjugated (using liquid chromatography-mass spectrometry (LC-MS/MS)) steroids including adrenal precursors (DHEA, DHEA-S, 4-dione, 5-diol), androgens (testosterone, DHT, ADT, ADT-G, 3a-diol-3G, 3a-diol-17G) and parent estrogens (E 1 -S, E 1 , E 2 ) (Fig.1 ). Steroid hormones were detected above the LLOQ for all cases. None of these steroids measured prior or after surgery were associated with clinicopathological characteristics, i.e.
histological type, grade, stage, lymph-vascular space invasion and metastases. Consistent with the notion that adipose tissue is a major source of estrogens in postmenopausal women; E 2 levels were 3.3-fold higher in obese EC cases (P<0.001) compared to those of normal weight (Fig.2a) . A similar trend was observed for the other parent estrogens E 1 -S and E 1 . This observation is in line with the significant association between BMI and low-grade (1 and 2) endometrial tumors (c 2 df=4 =28.9, P<0.001), mainly characterizing Type I adenocarcinomas. In contrast, for both Type I and Type II cases, circulating levels of adrenal precursors and androgens were not significantly associated with obesity, except for levels of 3a-diol glucuronide metabolites derived from the potent androgen dihydrotestosterone (DHT) (Supplemental Table 3 ).
LC-MS/MS-based analysis was also used to profile 14 catechol estrogen derivatives in preoperative and postoperative serums of EC cases. Note that only steroid concentrations accurately measured above the LLOQ of 5 pg/mL were considered as detectable. Detection rates are presented in Table 3 and were similar in preoperative and postoperative serums. In particular, four metabolites were most abundant and detected in more than 60% of EC cases, namely E 3 , 2OH-E 1 , 2MeO-E 1 and 4MeO-E 2 . As observed for the parent estrogens E 1 and E 2 , levels of these catechol estrogens were significantly affected by BMI, except 4MeO-E 2 , which remained constant across BMI categories (Fig.2b) . In relation to clinicopathological characteristics, a significant association was only observed for E 3 , which levels were 1.6-fold lower in myoinvasive tumors (≥50%) compared to less myoinvasive tumors (<50%) (21.0 vs 33.2 pg/mL, P=0.011; adjusted for age and BMI). Compared to cases with preoperative E 3 levels below median (≤30.5 pg/mL), those with higher levels (>30.5 pg/mL) were less likely to experience recurrence after surgery (Log-rank P=0.001) during the 5 years following diagnostic; an association that remained significant in the fully adjusted model for all available follow-up (HR=0.27, 95% CI=0.09-0.80; P=0.018; Table 4 ). Preoperative levels of E 3 were also linked to an improved OS, as shown by the Kaplan-Meier curves for OS within 5 years post surgery (Log-rank P=0.002; Fig.3b ) and for all available follow-up (Log-rank P=0.021; Supplemental Table 5 ). Furthermore, levels of the abundant estrogen precursor E 1 -S were associated with a higher risk of recurrence (HR=2.67, 95%
CI=1.02-6.99; P=0.045; Fig.3a) . Of note, circulating levels of E 1 -S and E 3 were not significantly correlated (not shown).
One month after surgery, nearly all hormone levels were considerably reduced compared to preoperative levels ( Fig.3d ; Table 4 ). Hence, postoperative E 1 -S and E 3 levels were not associated with recurrence in the fully adjusted model ( Fig.3a ; Supplemental Table 4 ). In contrast, postoperative serum levels of the anticancer metabolite 4MeO-E 2 were significantly increased compared to preoperative levels, with a mean variation of 35% and a median elevation of 6.3 pg/mL (paired data of 187 EC cases). Moreover, EC cases with higher postoperative levels of 4MeO-E 2 were less likely to experience recurrence upon adjustment for prognostic factors in multivariate analysis (HR=0.34, 95% CI=0.14-0.86; P=0.022; Fig.3a) .
Lastly, postoperative levels of the androgen inactive metabolite 3a-diol-17G were linked to an improved OS (HR=0.26, 95% CI=0.07-0.89; P=0.031), whereas preoperative levels were not (Supplemental Table   5 ).
EC cases have higher levels of circulating steroid hormones compared to healthy women
In a last series of analyses, preoperative levels of steroids in EC cases were compared to those of 110 healthy postmenopausal women (Supplemental Tables 1-2 ) [15] . After adjustment for parity, use of oral contraceptives (OC), use of hormone replacement therapy (HRT), as well as age and BMI, levels of endogenous steroids were significantly associated with increased odds of EC, for both histological types, with ORs ranging from 2.19 to 17.07 (Fig.4) (Fig.2c ).
Discussion
In this study, we profiled by MS a total of 27 steroid derivatives including adrenal precursors, androgens, parent estrogens and catechol estrogens in circulation of postmenopausal women newly diagnosed with EC undergoing hysterectomy for curative intent. Despite the exploratory nature of our study, to the best of our knowledge, this report provides one of the most comprehensive analysis of circulating steroid hormones by MS in the context of EC, and is the first to report steroid levels prior and after surgery in relation to clinicopathological characteristics, recurrence and survival.
None of the steroids measured were associated with known prognostic factors, except E 3 , for which higher levels (>30.5 pg/mL) were linked to non-myoinvasive tumors, lower risk of recurrence and improved OS. This contrasts with higher levels of the most abundant estrogen precursor E 1 -S (>0.31 ng/mL), which were associated with an increased risk of relapse, in line with the role of E 1 -S as a predominant source of E 2 for endometrial tumor cells, and the proliferative effect of estrogens. Similar to the parent estrogens E 1 and E 2 , levels of catechol estrogens varied according to BMI, except for 4MeO-E 2 . In fact, this anticancer metabolite was the only steroid increased in circulation of EC cases after surgery with postoperative 4MeO-E 2 levels significantly associated with a lower risk of recurrence. Our observations require further investigations but imply that circulating levels of specific E 2 metabolites, namely E 1 -S, E 3 and 4MeO-E 2 , may represent independent prognostic markers of cancer recurrence after curative therapy.
Other groups reported similar levels of E 2 derivatives in circulation of endometrial, ovarian and breast cancer cases, as well as for healthy postmenopausal women [14, [20] [21] [22] [23] . In our study, preoperative levels of E 1 -S and E 3 were inversely associated with recurrence, in line with their opposing biological roles and the stimulatory action of E 2 on EC cells. High levels of the most abundant circulating estrogen E 1 -S were associated with poor outcome. An increased exposure to this estrogen precursor may favour E 2 synthesis and enhance stimulatory effect on tumor cells. In contrast, cases with higher levels of the E 2 metabolite, E 3 , were less likely to experience recurrence. The protective role of E 3 is reinforced by its inverse relationship with myometrium invasion whereas higher E 3 level persisted as an independent marker after adjusting for well-known prognostic factors. E 3 displays modest and mixed antagonist and agonist estrogenic activities in addition to immunological effects [24] [25] [26] . Recent studies support that EC cancer, and particularly the most aggressive forms of the disease, are sufficiently immunogenic to be candidate for immunomodulation [27] . It is thus possible that fluctuations of E 3 in this particular microenvironment might affect angiogenic profile and/or antitumor immunity.
In the analysis of E 2 derivatives in serums collected one month after surgery, we observed that postoperative levels of 4MeO-E 2 predicted risk of relapse independently of prognostic factors. In contrast to quantities of all other steroids, including levels of E 1 -S and E 3 that considerably declined after surgery, those of 4MeO-E 2 increased, and EC cases with higher levels were less likely to experience recurrence.
This observation could be explained by the fact that an increased methylation activity would reduce the genotoxic effects of 4-hydroxylation pathway catechols such as 4OH-E 2 through a decrease of their levels [11] . In line, less extensive methylation is associated with a higher risk of postmenopausal breast cancer whereas enhanced 2-hydroxylation is associated with a lower risk [28, 29] . Furthermore, concentrations of 4MeO-E 2 were not influenced by obesity by opposition to other estrogens, suggesting that its synthesis would not predominantly originate from adipose tissue. supporting that a significant portion of the steroidogenic activity is driven by the presence of the primary tumor. Besides, local estrogen synthesis in EC tumors has been established to occur predominantly through conversion of E 1 -S to E 2 compared to androgen aromatization by the aromatase (CYP19), which expression is barely detectable in EC tumors [7] . Adipose tissue is a primary site of aromatization after menopause, consistent with a greater concentration of potent estrogens and several of their metabolites in obese women, whom had higher odds of Type I endometrioid adenocarcinomas, in line with previous studies [35] [36] [37] [38] [39] . In turns, reduced SHBG levels in cancer cases may also contribute to the increased bioavailability of potent steroids [40] . EC cases diagnosed with non-endometrioid type II lesions also presented with significantly higher levels of adrenal precursors and androgens but not estrogens, suggesting an influence of the tumor on the adrenal secretion and on peripheral conversion of adrenal precursors to androgens with no subsequent impact on aromatization. This is in agreement with recent studies sustaining that androgens may play an etiological role in Type II EC, independent of their conversion to estrogens [41] [42] [43] . Furthermore, certain risk factors such as cigarette smoking and alcohol intake might influence cancer risk by altering adrenal precursors and androgen levels [44] .
Our study has several strengths including long follow-up period and detailed clinicopathological parameters, and to the best of our knowledge, is the only prospective study of estrogen metabolism in the context of EC outcome. We further used fully validated sensitive and specific bioanalytical methods based on mass spectrometry to yield reliable results and portrait a vast array of steroids including precursors, potent androgens and estrogens, and their biologically active and inactive metabolites. Our study excluded cases that have taken HRT prior to surgery to avoid potential confounding effects on hormonal assays. The analytical assay for catechol estrogens was based on a method published by Xu et al.
[18] that reported a LLOQ for each estrogen metabolite in serum of 8 pg/mL (~29 pmol/L) using 500 uL of serum for extraction. Here, we used 250 uL with a LLOQ of 5 pg/mL (~18 pmol/L). In our study, only levels of catechol estrogens quantitatively determined with suitable precision and accuracy were reported (i.e. above LLOQ). Likewise, our statistical analyses were limited to metabolites detected in most EC cases in order to avoid biases caused by potentially unreliable steroid concentrations measured above detection limit but below LLOQ, potentially corresponding to semi-quantitative or qualitative data [45] .
Finally, we are not aware of other studies reporting changes in circulating steroids after curative surgery for EC cases. Limitations of our study need to be considered and include a limited number of relapse events (10%), which prevented us to apply multiple testing adjustments. Also, because of a small number of events, cancer-specific survival could not be assessed and we were unable to determine the association of hormone levels with outcomes by histologic subtypes that may vary. Furthermore, assessment of hormone levels was performed after disease onset and compared to a limited number of healthy postmenopausal women. A single hormone measurement at two different time points was performed with samples from EC cases collected the morning of the surgery and one month after. In addition, BMI has not been assessed at follow-up visit one month after surgery, preventing us from correcting for this potential confounding factor.
In conclusion, despite the exploratory nature of our study, it may help establish a non-invasive stratification of patients as high-risk and low-risk categories using preoperative and postoperative measures of circulating steroids, which could be repeated during follow-up. In addition, a better understanding of estrogen metabolism may provide insights into the mechanisms underlying EC progression. Additional larger studies are warranted to elucidate the relationships between estrogen levels, recurrence and survival of EC cases undergoing hysterectomy for curative intent.
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Supplemental
1 Risk of poor prognosis is categorized as low-risk corresponding to type I (TI) with low-grade G1 and G2
whereas TI-G3 and TII are considered as high risk.
2 P-value is derived from a chi-square test. Significant differences are indicated in bold. Detection is defined as levels of estrogens above the lower limit of quantification of 5 pg/mL (LLOQ).
Catechol estrogens above LLOQ in the majority of cases (shaded grey) were the focus of subsequent analyses. 2 Variation in hormone levels between pre-and post-operative levels were established using Wilcoxon signed rank test for paired data.
n/a: not available. ADT and catechol estrogens could not be measured in healthy postmenopausal women. Significant differences are indicated in bold.
a P < 0.001; b P < 0.01; c P < 0.05. All-cause mortality. LR P: Log-rank P from Kaplan-Meier analysis for all available follow-up; HR adj : Hazard ratio and 95% confidence interval (95% CI), calculated with Cox regression for all available follow-up and adjusted for age, BMI, low/high risk categories, metastases, lymph-vascular space invasion (LVSI) and recurrence; Low/High risk: TI-G1/G2 are categorized as low risk, while TI-G3 and TII are high risk. HR Fadj : Cox regression was calculated as above, and was further adjusted for SHBG levels. Results that are significant in either adjusted models are shaded in grey. When hazard ratio and 95% CI were calculated with a 5-year follow-up after surgery, results were similar.
